

Supplementary material for:

Rational design of MPER lipopeptides containing chemical modifications
for HIV-1 vaccination

Vincent J. Venditto^{1,†}, Douglas S. Watson^{1,2,3,†}, Michael Motion^{1,2}, David Montefiori⁴

and Francis C. Szoka, Jr.^{1,*}


¹Departments of Bioengineering and Therapeutic Sciences, School of Pharmacy, University of California, San Francisco, California 94143-0912; ²Joint Graduate Group in Bioengineering, UC San Francisco / UC Berkeley, San Francisco, California, 94143-0912; ³Present Address: Merck & Co., Inc., Elkton, VA 22827; ⁴Department of Surgery, Duke University Medical Center, Durham, NC 27710. [†]V.J. Venditto and D.S. Watson contributed equally to this work.

Table of Contents:

- Figure S1 Representative surface plasmon resonance sensorgram data
- Figure S2 CD spectra of modified and unmodified peptides in liposomal formulations
- Figure S3 Rabbit reciprocal endpoint titers over time
- Figure S4 Day 115 rabbit reciprocal endpoint titers verse different modified immunogens


- Table S1 Rabbit antisera viral neutralization data

Figure S1: Representative surface plasmon resonance sensogram data: N-MPER(S-PO₃)



BIAcore binding data. Overlaid sensorgrams of N-MPER(S-PO₃) at concentrations ranging from 200nM to 12.5 nM interacting with monoclonal antibody, 2F5, immobilized on a Series S CM5 sensor chip. Antibody immobilization was ~4000 with 90 second analyte injection time and 110 second wash with running buffer (Hepes Buffered Saline containing 0.01% tween-20) before regeneration with 2M guanadinium hydrochloride.


Figure S2: CD spectra of modified and unmodified peptides in liposomal formulations



Circular Dichroism of Liposomal Lipopeptides. Each line corresponds to an average of three scans.


Liposomes in the absence of lipopeptides have been subtracted from background. Wavelengths are in nm.

Figure S3: Reactivity of endpoint sera against side chain modified lipopeptide immunogens



Endpoint reciprocal titers of immunized rabbits over time. Each line corresponds to endpoint reciprocal antibody titers of one rabbit against the respective immunogen over time. Each symbol corresponds to a single animal and values are the average of duplicate ELISAs.

Figure S4: Day 115 Rabbit reciprocal endpoint titers verse different modified immunogens



Endpoint reciprocal titers of immunized rabbits. Each series corresponds to day 115 antibody titers for one rabbit against each immobilized peptide on the X-axis. Lines are the average values of duplicate ELISA runs.

Table S1: Rabbit antisera viral neutralization data

		ID50 in TZM-bl cells				ID50 in A3R5.7 cells	
		SVA-MLV (ID#2642)	SF162.LS (ID#1721)	SC22.3C2.LucR.T2A.ecto Clade B Tier 2 (ID#3868)	RHPA.LucR.T2A.ecto Clade B Tier 2 (ID#4523)	CH77.LucR.T2A.ecto Clade C Tier 1 (ID#4393)	CH58.LucR.T2A.ecto Clade C Tier 1B (ID#3825)
Bleed Day	N-MPERext						
1	0	<20	<20	35	<20	231	83
	115	<20	<20	35	24	426	87
2	0	<20	<20	29	<20	315	66
	115	<20	<20	29	<20	175	65
3	0	<20	<20	63	25	196	113
	115	24	<20	47	28	145	59
1	0	<20	<20	31	<20	195	68
	115	<20	<20	32	34	170	70
2	0	<20	<20	22	<20	263	58
	115	<20	<20	31	<20	342	85
3	0	<20	<20	21	<20	370	76
	115	<20	<20	29	<20	1166	79
1	0	<20	<20	<20	<20	513	58
	115	<20	<20	27	22	451	72
2	0	<20	<20	36	<20	311	97
	115	<20	<20	<20	23	70	38
3	0	<20	<20	30	20	518	80
	115	<20	<20	35	26	380	67
1	0	<20	<20	<20	<20	39	<20
	115	<20	<20	42	23	322	90
2	0	<20	<20	26	21	176	60
	115	<20	<20	33	26	161	52
3	0	<20	<20	27	<20	149	50
	115	<20	<20	31	23	117	51
1	0	<20	<20	25	<20	408	86
	115	<20	<20	36	21	363	85
2	0	<20	<20	27	<20	1219	113
	115	<20	<20	33	<20	623	74
3	0	<20	<20	24	<20	110	40
	115	<20	<20	28	<20	82	38